
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is a leader in biotechnology-based human therapeutics, with a strong portfolio of flagship drugs including Epogen, Aranesp, Neupogen, Neulasta, Enbrel, and Otezla. Recent launches, such as Repatha, Aimovig, Lumakras, and Tezspire, have bolstered the company's offerings. The acquisition of Onyx Pharmaceuticals and 2023 Horizon has also added a diverse range of rare-disease drugs. Positive trends in key metrics, such as Repatha's growing total and new prescriptions, and the potential of Tepezza's self-administered option could further boost Amgen's growth potential.
Bears say
Amgen is facing headwinds in 2026 due to biosimilar/generic competition and weak script trends for Prolia, Xgeva, and Otezla. However, with the anticipated label expansion for Tezspire in chronic rhinosinusitis with nasal polyps and potential for growth in eosinophilic esophagitis and asthma treatment with TSLP-directed drug AMG 104, the company’s outlook may improve in the long term. Despite strong performances from products like Evenity, Tavneos, and Lumakras, the current challenges and weak script trends prompt a neutral rating and a price target of $351 per share.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares